Vaginal estrogen safety under scrutiny: new study targets blood clot risk
NCT ID NCT07160504
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study looks at whether vaginal estrogen tablets, used to treat vaginal atrophy, change blood clotting factors in postmenopausal women. Researchers will take blood samples before and after 3 months of treatment. The goal is to see if this common treatment might raise or lower the risk of blood clots, especially in women who have had a clot before.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- vaginal estradiol tablets
- What this could lead to
- If it works, this could clarify whether local vaginal estrogen is safe for women with a history of blood clots.
- What could go wrong
- This is a small, early-phase study focused on lab markers, not clinical outcomes. Results may not change current practice.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for VAGINA ATROPHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Department of Obstetrics and Gynecology, Aarhus University Hospital, Denmark
RECRUITINGAarhus N, 8200, Denmark